A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia
Phase: PHASE2
Conditions: Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure, Immunosuppression
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Version date: 08/24/2020 
 
TITLE: Regenerative Medicine to Restore Normal Hematopoiesis in Aplastic Anemia 
 
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-
Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Newly Diagnosed Patients 
with Severe Aplastic Anemia 
 
Protocol Number:   
J1688  
 
IRB Application#: IRB00107139 
NCT#: 02833805 
 
Principal Investigator: Amy E. DeZern, MD, MHS 
 
 
 
Office: 410-502-7208 
 
 
 
Pager:  410-283-7521 
 
 
 
Email: adezern1@jhmi.edu 
 
Statisticians:  
 
Gary L Rosner, ScD              
Marianna Zahurak, MS 
 
Version date:  
Version 1.5 6/7/2017 
 
Protocol history: 
Version 1.0 7/26/16 
Version 1.1 2/10/17 
Version 1.2 3/7/2017 
Version 1.3 3/30/2017 
Version 1.4 4/17/2017 
Version 1.5 12/31/2017 
 
 
 
 
 
 
 
 
 
 

2 
 
 
 
 
 
 
 
 
Treatment Schema 
Days -9                      
   Thymoglobulin 0.5 mg/kg IV with pre-meds 
 
Days -8,-7 
Thymoglobulin 2 mg/kg IV daily with pre-meds 
 
Days -6, -5 
Fludarabine 30 mg/M2 IV daily (adjusted for renal function) 
 
Cyclophosphamide (CTX) 14.5 mg/kg IV daily 
 
Start steroid taper from ATG 
 
Days –4→ -2 
Fludarabine 30 mg/M2 IV daily (adjusted for renal function) 
Day –1 
TBI 400 cGy 
 
Day 0 
Infuse bone marrow per institutional standards  
 
Begin antibiotic prophylaxis 
 
 
Days 3, 4 
Cyclophosphamide 50 mg/kg IV daily 
 
Mesna 40 mg/kg IV daily 
(First dose of cyclophosphamide must be administered 60-72 hr after START of infusion of marrow) 
 
 
Day 5    
Begin tacrolimus (section 2.5.3.2)  
                
Begin MMF 15 mg/kg PO TID (maximum daily dose 3 g/day) 
 
(At least 24 hours after the last dose of CY) 
 
 
Day 28 
Assess Chimerism in peripheral blood, assess GVHD 
 
 
Day 35  
 
 
 
Discontinue MMF 
 
 
Day 56 
          Assess Chimerism in peripheral blood and bone marrow (with biopsy) 
 
Assess GVHD 
 
 
Day 84 
Evaluate disease 
 
 
   Assess Chimerism in peripheral blood, assess GVHD 
 
 
Day 112 
Evaluate disease 
 
 
   Assess Chimerism in peripheral blood, assess GVHD 
 
 
Day 180 
Evaluate disease 
 
 
   Assess Chimerism in peripheral blood, assess GVHD 
 
 
Day 365           
Discontinue tacrolimus if no GVHD and full chimera 
 
Evaluate disease 
 
 
   Assess Chimerism in peripheral blood and bone marrow 
 
 
 

3 
 
 
 
 
 
 
 
 
Contents 
Treatment Schema ........................................................................................................................ 2 
1. 
Background ........................................................................................................................... 4 
1.1. 
Bone marrow transplantation for SAA............................................................................ 4 
1.2. 
Regimen for BMT in SAA ............................................................................................... 5 
2. 
Study Design .......................................................................................................................... 6 
2.1. 
Study Overview ................................................................................................................ 6 
2.2. 
Hypotheses and Objectives .............................................................................................. 6 
2.2.2. 
Objectives .................................................................... Error! Bookmark not defined. 
2.3. 
Eligibility Criteria for Enrollment .................................................................................... 7 
2.3.1. 
Inclusion Criteria .......................................................................................................... 7 
2.3.2. 
Exclusion Criteria ......................................................................................................... 8 
2.4. 
Donor Selection ................................................................................................................ 9 
2.5. 
Treatment Plan ................................................................................................................. 9 
2.5.1. 
Conditioning for Bone Marrow Recipients ................................................................ 10 
2.5.2. 
Donor Marrow Product Handling and Infusion .......................................................... 10 
2.5.3. 
GVHD Prophylaxis..................................................................................................... 10 
2.5.4. 
GVHD Treatment ....................................................................................................... 11 
2.5.5. 
Supportive Care .......................................................................................................... 11 
2.5.6. 
Risks and Toxicities.................................................................................................... 12 
3. 
STUDY ENDPOINTS AND DEFINITIONS.................................................................... 15 
3.1. 
Primary Endpoint ........................................................................................................... 15 
3.2. 
Secondary Endpoints ...................................................................................................... 15 
3.3. 
Study Monitoring ........................................................................................................... 18 
3.3.1. 
Follow-up Schedule .................................................................................................... 18 
3.3.2. 
Patient Evaluations ..................................................................................................... 18 
4. 
STATISTICAL CONSIDERATIONS .............................................................................. 21 
5. 
DATA MANAGEMENT .................................................................................................... 27 
5.1. 
Data and Safety Monitoring ........................................................................................... 27 
5.2. 
Internal Data Monitoring and Adverse Event reporting................................................. 27 
5.3. 
External Data Monitoring and Auditing......................................................................... 28 
5.4. 
Safety Monitoring .......................................................................................................... 28 
5.5. 
Risks and Benefits .......................................................................................................... 29 
5.6. 
Informed Consent ........................................................................................................... 29 

4 
 
 
 
 
 
 
 
 
5.7. 
On-study Date ................................................................................................................ 29 
5.8. 
Off-study Date ................................................................................................................ 29 
Appendix 1. Consensus conference clinical grading of acute GVHD .................................... 31 
Appendix 2. Ideal Body Weight and Adjusted Ideal Body Weight Calculations ................. 32 
References Cited.......................................................................................................................... 33 
 
1. Background 
Bone marrow failure (BMF) syndromes (acquired and inherited) are a heterogeneous group of disorders 
marked by ineffective hematopoiesis76. They confer a significant risk of morbidity and death, due to their 
progressive natural history and complications of suboptimal therapy.2, 76 Acquired severe aplastic anemia 
(SAA) is a rare, life-threatening hematopoietic stem cell disorder that manifests with pancytopenia and a 
hypocellular bone marrow.5, 20 In most cases (acquired), bone marrow failure is believed to result from 
autoimmune destruction of hematopoietic stem cells5. Without definitive treatment, mortality from SAA 
approaches 70% at two years. Fungal infections are the leading cause of death; however, hemorrhage, 
evolution to clonal disease (myelodysplastic syndromes [MDS], leukemia, and paroxysmal nocturnal 
hemoglobinuria [PNH]), and transfusional iron overload are other causes of severe morbidity and 
mortality. Inherited bone marrow failure syndromes (IBMFS) from disorders such as short telomeres 
(dyskeratosis congenital [DKC]), Fanconi anemia and other congenital SAA also carries the risk of infection 
and clonal evolution to MDS. These patients have long pursued BMT as a therapeutic avenue but are 
limited still by availability of matched sibling donor. Goals of upfront therapy should include availability 
to all patients and avoidance of possibility of clonal evolution. 
SAA affects all ages, but is most common in children and young adults. Blood or marrow transplantation 
(BMT) from an HLA-matched sibling donor can cure the vast majority of patients with SAA, but fewer than 
30% of patients have a suitable HLA-matched sibling. Moreover, the best results with allogeneic BMT are 
in children; adults, especially those over age 40, do less well due to complications from graft-versus-host 
disease (GVHD). Alternative donor transplants (mismatched and unrelated donors) also have the potential 
to cure SAA, but are historically have been reserved for second-line therapy because of their high rates of 
morbidity and mortality. For SAA patients who lack matched sibling donors or are not good candidates for 
BMT, immunosuppressive therapy can also be effective. Currently, patients with acquired SAA, not 
responsive to initial IST, or inherited AA lacking other treatments options require have required 
alternative donor transplants. This is becoming more and more feasible and safe. The goal now is to 
possibly eliminate the need for IST in all patients by moving more efficiently and safely to up front BMT. 
An approach to BMT using post-transplant CY has allowed allogeneic BMT from matched, mismatched, 
unrelated or haplo-identical donors in other diseases.38, 39, 41 Transplant-related mortality, graft-failure 
rates and risk of GVHD have been very low with this approach with non-myeloablative conditioning. 
Here we use alternative donors with CY post BMT to decrease GVHD to expand the donor pool in AA and 
move alternative donors to the upfront setting. 
1.1. Bone marrow transplantation for SAA 
Allogeneic BMT from an HLA-matched sibling donor is the treatment of choice at most centers for young 
patients with SAA. A major advantage of BMT over standard IST is a marked reduction in the risk of relapse 
and the outgrowth of late clonal disorders such as MDS/AML and PNH18. The overall transplant related 

5 
 
 
 
 
 
 
 
 
mortality (TRM) attributable to HLA-identical sibling BMT is low (10%) and the incidence of severe, grade 
III-IV acute GVHD is approximately 10-20% after HLA-identical sibling BMT.6, 15   
Historically, unrelated donors and mismatched or haplo- transplants have almost twice the transplant-
related mortality and risk of GVHD as matched sibling donor transplants in SAA2. Despite the fact that only 
30% of people have matched donors and the average person has 4.5 haplo-identical donors, these 
statistics have limited the use of these alternative donors. The best results with unrelated and mismatched 
transplants are seen in patients under 21 with disease duration of less than one year.15  
1.2. Regimen for BMT in SAA 
The ideal BMT regimen is one that results in sustained engraftment, minimal toxicity from the regimen, 
lack of acute or chronic GVHD and allows the majority of patients (old and young) to proceed efficiently 
to this potentially curative option. 
Conditioning: Various conditioning regimens have been employed over the years for transplants to 
patients with SAA with failure to engraft and GVHD as the main obstacles to success. The current approach 
used here is one that has been successfully used as above in sickle cell disease.4 Historically, TBI- based 
conditioning regimens reduced the risk of graft rejection but increased GVHD and other late effects.16 
Standard ATG-based conditioning regimens are employed to aid in engraftment but have also been 
associated with up to a 30% incidence of cGVHD.8, 11 Fludarabine has been used in conditioning for patients 
with both acquired and constitutional aplastic anemia with good results.9, 10, 14, 19  
Choice of Stem Cells: This trial will utilize bone marrow as the stem cell source. The EBMT reviewed 
outcomes in nearly 700 patients with SAA receiving transplants from HLA-matched siblings. In patients 
younger than 20 years of age, rates of chronic GVHD (relative risk 2.82; p = 0.002) and overall mortality 
(relative risk 2.04; p = 0.024) were higher after transplantation of peripheral blood progenitor cell grafts 
than after transplantation of bone marrow. In younger patients, the 5-year survival was 85% after marrow 
transplants but only 73% after peripheral blood progenitor cell grafts. These data suggest that bone 
marrow grafts are preferable in this age group3, 17.  
GVHD prophylaxis: An approach to BMT at Hopkins using post-transplant cyclophosphamide has allowed 
for transplantation of allogeneic BMT from matched, mismatched, unrelated or haplo-identical donors in 
both malignant and non-malignant diseases.4, 12, 13  The administration of a properly timed, high dose of 
CY after BMT inhibits both graft rejection and GVHD19-22. It is customary for IST for GVHD to continue post-
transplant through one year in SAA.1  
Using the regimen specified in this proposal (with 4.5 mg/kg of Thymoglobulin® over three days) 
developed at Johns Hopkins, ten refractory or relapsed patients to date have been treated. The median 
age of these patients at the time of transplant was 35 years (range 17-54). All are currently alive with 
median follow up of 12.5 months (range 3-44). All patients engrafted with the median time to ANC >500 
of 15 days (14-20). Median time to red cell independence was 23.5 days (range 16-58) and median time 
to platelet engraftment (defined as greater than 50,000 platelets for seven days without transfusion) was 
29.5 days (range 22-108). All patients were 100% donor chimerism by day 100. Two patients had grade 1-
2 skin aGVHD (22%). Two patients also had cGVHD (22%) grade 2 of the skin and mouth. One patient was 
able to come off immunosuppression by 15 months and the other by 18 months.  
In conclusion, the major challenge in treating SAA (inherited and acquired) is the management of patients 
who are refractory to IST, have relapsed after IST, or who have acquired a secondary clonal disorder 

6 
 
 
 
 
 
 
 
 
(MDS/PNH) after IST. The time lost with ineffective IST as well as the risk of acquired secondary clonal 
disorders as well as more rapid immune reconstitution can be a benefit of upfront BMT for all SAA 
patients. Given that BMT is the only curative option for these patients, the proposed regimen eliminates 
patientineligibility because they lack a suitable donor or are too high risk for BMT due to the risk GVHD. 
Here we seek to increase options for these patients by developing novel therapeutic strategies to treat 
rSAA with expansion of the donor pool through minimization of the post-transplant complication of GVHD. 
Present above are promising results in the non-myeloablative haplo-identical setting for relapsed and 
refractory SAA with a low incidence of engraftment failure, severe acute GVHD, extensive chronic GVHD, 
and NRM utilizing post-transplantation CY. This trial will employ this non-myeloablative conditioning 
regimen along with post-transplantation CY on days +3 and +4 for patients with SAA in the upfront, 
treatment naïve setting. We anticipate HiCY will likely ameliorate the GVHD while the combination of ATG, 
fludarabine and TBI will allow for engraftment.   Furthermore, this approach allows us to greatly expand 
the donor pool since any patient shares exactly one HLA haplotype with each biological parent or child 
and half of siblings, an eligible haplo-identical donor can be identified rapidly in the majority of patients. 
This also allows older patients to use a matched sibling donor upfront or a patient with an inherited 
marrow failure syndrome to use an unrelated donor with lower rates of GVHD. This is of great benefit to 
aplastic patients as time to treatment will be shorter and presumed avoidance of longer term 
complications post IST such as clonal evolution. The purpose of the current trial is to improve response 
rates and cure for in SAA similar to matched sibling transplant upfront. 
2. Study Design 
2.1. Study Overview 
2.2. This study is a prospective phase II study to assess if it is feasible for previously untreated SAA 
patients to be transplanted using non-myeloablative conditioning and post transplantation 
cyclophosphamide.  
2.3. Hypotheses and Objectives 
2.3.1. Primary Hypothesis Using ATG dose (4.5 mg/kg) together with fludarabine/cyclophosphamide/ TBI 
and post-BMT cyclophosphamide,we will determine if it is feasible for previously untreated SAA 
patients to be transplanted using non-myeloablative conditioning and post transplantation 
cyclophosphamide. 
. 
2.4. Primary Objective 
Our primary objective is to determine if it is feasible for previously untreated SAA patients to be 
transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide. 
 
2.5. Secondary Objectives 
2.5.1. To estimate overall survival at one year. 
2.5.2. To estimate full donor chimerism by day 60 
2.5.3. To estimate the cumulative incidence of non–relapse-related mortality following 
transplant. 
2.5.4. To estimate the incidences of primary and secondary graft failure following transplant. 
2.5.5. To estimate the cumulative incidences of grade II-IV and grade III-IV acute graft versus-
host disease (GVHD).  
2.5.6. To estimate the cumulative incidence of chronic graft versus-host disease (GVHD).  
2.5.7. To estimate the cumulative incidence of ANC and platelet recovery.  
2.5.8. To estimate GVHD free relapse free survival (GRFS). 

7 
 
 
 
 
 
 
 
 
2.5.9. To summarize major transplant related toxicities and to estimate transplant related 
mortality (TRM). 
 
 
2.6. Eligibility Criteria for Enrollment 
2.6.1. Inclusion Criteria  
Patients will be enrolled regardless of gender or age. Additional inclusion criteria are: 
1. Confirmed diagnosis of SAA (acquired or inherited), either from initial diagnosis or follow-
up assessments, defined as:7 
a. Bone marrow hypocellularity is required and relative to patient’s age 
(normocellularity is 100- patient age in years). 
(Often marrow cellularity <50% but with <30% residual hematopoietic cells may 
be applied where appropriate at the discretion of the PI) 
b. Two out of three of the following (in peripheral blood): neutrophils <0.5 x109/L, 
platelets <20 x109/L (without transfusions), reticulocyte count <60 x109/L. 
2. No suitable fully matched related (6/6 match for HLA-A and B at intermediate or high 
resolution and DRB1 at high resolution using DNA based typing) donor if under age 25 
years. 
3. Available donor as follows: 
a. HLA haploidentical relative of the patient. A unidirectional mismatch in either the 
graft versus host or host versus graft direction is considered a mismatch. The 
donor and recipient must be identical at least one allele (high resolution DNA-
based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1. See section 
2.4 for additional information.  
b. If patient over age 25 years, may use HLA identical sibling donor. 
c. If patient has inherited bone marrow failure syndrome (IBMFS) and clear 
evidence of same disorder in potential related donors, unrelated donor may be 
used. Unrelated donor must be a 10/10 match using HLA-A, -B, -C, DRB1, and 
DPB1. Unrelated donor may also be used in case of donor specific antibodies to 
related donors or other clinical causes of unsuitable related donors. 
 
4. Patient and/or legal guardian must sign informed consent for BMT.  
5. The potential donor must be willing to donate bone marrow. 
6. Adequate organ function defined as: 
a. Cardiac:  
i. Left ventricular ejection fraction (LVEF) at rest ≥40%. For patients aged 
<13 years, shortening fraction (SF) ≥26% by echocardiogram or LVEF by 
MUGA may be used. 
 

8 
 
 
 
 
 
 
 
 
b. Hepatic:  
i. Total bilirubin <3.0 x the upper limit of normal (ULN) for age (patients 
who have been diagnosed with Gilbert’s Disease are allowed to exceed 
this limit)  
 
ii. AST and ALT <5.0 x ULN for age 
c. Renal: 
i. 
For patients >13.0 years of age at the time of enrollment: estimated 
creatinine clearance >50 mL/minute (using the Cockcroft-Gault 
formula and actual body weight). 
ii. 
For patients >1.0 year of age but <13.0 years of age at the time of 
enrollment: GFR estimated by the updated Schwartz formula ≥90 
mL/min/1.73 m2. If the estimated GFR is <90 mL/min/1.73 m2, then 
renal function must be measured by 24-hour creatinine clearance 
or nuclear GFR, and must be >50 mL/min/1.73 m2. 
d. Pulmonary  
i. 
For patients > 8 years of age (or otherwise able to complete 
pulmonary function testing per established American Thoracic 
Society standards), DLCO (corrected/adjusted for hemoglobin) 
>40% and FEV1 >50% predicted (without administration of 
bronchodilator) and FVC >50% predicted.  
ii. 
For patients <8years of age unable to perform PFTs due to age or 
developmental ability: (1) no evidence of dyspnea at rest and (2) 
no need for supplemental oxygen and (3) O2 saturation >92% on 
room air. 
7. Karnofsky or Lansky performance status ≥ 70% 
8. Females and males of childbearing potential must agree to practice 2 effective methods 
of contraception at the same time, or agree to abstinence.  
2.6.2. Exclusion Criteria 
1. Patient with previous administration of immunosuppressive therapy for SAA. 
2. Patients with Fanconi anemia. At a minimum, the diagnosis of Fanconi anemia must be 
excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow in 
patients younger than 30 years of age. (Additional mutational testing may have been 
performed in a clinical or research capacity on a per patient basis but is not considered 
an exclusion criteria) 
3. Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome (pre-
MDS) or MDS on marrow examination (e.g. Monosomy 7). 
4. Presence of anti-donor HLA antibodies (positive anti-donor HLA antibody is defined as a 
positive cross-match test of any titer by complement-dependent cytotoxicity or flow 
cytometric testing or the presence of anti-donor HLA antibody to the high expression loci 
HLA-A, B, C, or DRB1 with mean fluorescence intensity (MFI) >1000 by solid phase 
immunoassay). 
5. Prior allogeneic stem cell transplant. 

9 
 
 
 
 
 
 
 
 
6. Prior solid organ transplant. 
7. Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled 
is defined as currently taking medication and with progression or no clinical improvement 
on adequate medical treatment. 
8. Seropositivity for the human immunodeficiency virus (HIV). 
9. Active Hepatitis B or C determined by serology and/or NAT 
10. Female patients who are diagnosed as pregnant by beta BCG testing (per institutional 
practice) or breast-feeding. 
11. Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in 
situ. Cancer treated with curative intent > 5 years previously will be allowed. Cancer 
treated with curative intent ≤ 5 years previously will not be allowed unless approved by 
the PI. 
2.7. Donor Selection 
1. Donor must be medically, socially, and psychologically fit to donate. 
2. Haploidentical donor will be prioritized where medically appropriate. 
a. Donors must be at least 5/10 HLA-matched relative. Donor selection is multi-faceted 
and takes into many variables such as donor health, donor age, and donor and 
recipient gender parity, CMV status, and ABO compatibility (see BMT Policy and 
Procedures Manual). 
b. Unrelated donors, where used, will also be chosen based on current institutional 
standards and must be 10/10 matches. (See BMT Policy and Procedures Manual).   
 
 
2.8. Treatment Plan 
 

10 
 
 
 
 
 
 
 
 
2.8.1.  Conditioning for Bone Marrow Recipients 
2.8.1.1. 
Thymoglobulin 
Thymoglobulin® preparation of ATG will be dosed by actual body weight. On day -9, thymoglobulin 0.5 
mg/kg is administered and 2 mg/kg on day -8 and day -7. The dose will be 0.5 mg/kg IV on day -9 over 6 
hours and 2mg/kg IV on days -8 and -7 over 4 hours. Premedication should follow local institutional 
practice, but should include a minimum of 1 mg/kg methylprednisolone in children or 100 mg in adults 
prior to the infusion (equivalent steroid allowed), preferably repeated in 3-4 hours during the infusion.  
2.8.1.2. 
Fludarabine 
Fludarabine 30 mg/m2 IV daily for 5 days, from day -6 to day -2 (total dose received 150 mg/m2), will be 
dosed on actual body weight. Fludarabine will be dosed according to the recipient’s actual body weight. 
Fludarabine should be dose-reduced based on creatinine clearance according to institutional standard of 
care. Fludarabine dosing is based on the last creatinine clearance prior to the start of conditioning. 
Fludarabine dose should not change on Days -6 to -2, unless the patients creatinine clearance changed 
but the Cockgroft Gault calculation by greater than 30% from baseline creatinine clearance. 
2.8.1.3. 
Pre-BMT Cyclophosphamide 
Hydration prior to cyclophosphamide may be given according to institutional standards. 
Cyclophosphamide 14.5 mg/kg IV daily for 2 days from day -6 to day -5 and administered as a 1-2 hour 
infusion (total dose received 29 mg/kg). Doses of cyclophosphamide and mesna are based on the patient’s 
IBW unless actual body weight is less than IBW, in which case use actual body weight. If the patient weighs 
more than 125% of IBW, cyclophosphamide will be doses according to the adjusted IBW. Hydration, as 
well as doses and schedule for uroprotective agents (i.e. mesna) may be administered per institutional 
practice.  
2.8.1.4. 
Total Body Irradiation 
Total body irradiation (TBI) will be delivered in a single dose of 400cGy on day -1. TBI may be delivered 
from either linear accelerator or Cobalt sources (per institutional practice).  
2.8.2. Donor Marrow Product Handling and Infusion 
Patients will receive unmanipulated marrow unless there is a major ABO incompatibility, in which case 
red blood cells will be depleted from the donor marrow using institutional practices. Institutional practices 
will determine if there will be processing for minor ABO incompatibilities. Donor bone marrow will be 
harvested with a target yield of 4 x108 nucleated cells per kilogram of recipient IBW and a minimum yield 
of 2.5 x108 nucleated cells per kilogram of recipient IBW. If the minimum yield is not obtained, patient will 
be removed from the study. It is recommended that no more than 10 mL per aspirate be taken. In addition 
to calculating the total nucleated cell dose per kilogram, a sample of the product to be infused will be sent 
for flow cytometry to determine the content of CD34+ cells. The use of cryopreserved marrow is not 
permitted.  
Note: The patient is not to receive steroids as an antiemetic or any other immunosuppressive agent 
from day 0 until at least 24 hours after completions of day +4 cyclophosphamide dose unless used for 
adrenal support or during medical emergency (e.g., treatment of anaphylaxis).  
2.8.3. GVHD Prophylaxis 
2.8.3.1. 
Post-BMT Cyclophosphamide 

11 
 
 
 
 
 
 
 
 
Cyclophosphamide 50 mg/kg IV daily will be given for 2 days, days +3 to +4 (total dose received 100 mg/kg) 
after transplantation. Doses of cyclophosphamide and mesna are based on IBW unless actual body weight 
is less than IBW, in which case use actual body weight. If the patient weighs more than 125% of IBW, 
cyclophosphamide will be doses according to the adjusted IBW. Hydration, as well as doses and schedule 
for uroprotective agents (i.e. mesna) should follow local institutional practice. (Mesna has generally been 
utilized for the Day 3 and Day 4 post BMT cyclophosphamide doses, but not for the lower pre-BMT 
cyclophosphamide doses) 
2.8.3.2. 
Tacrolimus   
For adult patients, Tacrolimus IV or PO (per institutional standards) should be started on day +5 (24 hours 
after the end of the infusion of the CY) and administered per institutional standards to maintain a level of 
10-15 ng/mL. Tacrolimus will be continued through day 365 and then stop without taper. 
2.8.3.3. 
MMF 
MMF 15 mg/kg PO TID up to 1 gm TID (or IV equivalent) starting on day +5, (24 hours after the end of the 
infusion of the CY)will be discontinued after the last dose on day +35. MMF dosing may continue if active 
GVHD is present. 
2.8.3.4. 
Growth factor use 
G-CSF will be given IV or SQ starting on day +5 at 5 mcg/kg/day until ANC is >1000 for 3 days. Additional 
GCSF may be administered as warranted if the counts nadir again later in the course. Pegfilgrastim 
(Neulasta)® and GM-CSF are not permitted. 
2.8.4. GVHD Treatment 
In the event of the development of either acute or chronic GVHD, therapy will be at the discretion of 
treating centers. 
2.8.5. Supportive Care 
2.8.5.1. 
Infectious disease prophylaxis 
Antifungal prophylaxis will be administered according to institutional practices. It is important to follow 
levels of tacrolimus for patients receiving one of the azole antifungal medications. The combination of 
both drugs can raise the levels of the immunosuppressant to toxic levels. If a patient on tacrolimus is 
started on an azole antifungal medication, a dose reduction of the tacrolimus is required and levels should 
be obtained to ensure they are not in the toxic range. 
Pneumocystis jiroveci pneumonia (PJP) prophylaxis will be administered according to institutional 
practices. Recommendations include starting approximately one month post-BMT (or later if WBC not 
recovering) and continuation until at least three months off of all immunosuppressive medications. 
Viral prophylaxis for herpes simplex virus (HSV) and varicella zoster virus (VZV) will be administered 
according to institutional practices. Recommendations include continuation for at least one year post-
BMT and/or while on immunosuppressive medications. 
Prophylactic and empiric antibiotics as well as intravenous immunoglobulin (IVIG) will be administered 
according to institutional practices. Re-immunization may be performed according to institutional 
practices. 
2.8.5.2. 
Infectious disease monitoring 

12 
 
 
 
 
 
 
 
 
CMV viremia as tested by DNA PCR will be monitored as per institutional standard. Patients who are 
viremic or show evidence of end organ CMV disease may be treated according to institutional practices. 
EBV viremia as tested by DNA PCR will be monitored per clinician discretion. If the patient becomes 
viremic with a DNA PCR level of 1000 copies/mL or higher on two consecutive occasions, recommendation 
includes the use of Rituximab (375 mg/m2 IV x1). If the patient develops persistent EBV viremia or 
signs/symptoms of EBV-related post-transplant lymphoproliferative disease (PTLD) despite rituximab 
administration, they may be treated according to institutional practices. 
HHV-6 viremia as tested by DNA PCR is suggested to be monitored weekly until day +60. If the patient 
becomes viremic, they may be treated according to institutional practices. 
2.8.5.3. 
Management of graft failure 
Patients experiencing primary or secondary graft failure may be managed according to institutional 
practices. 
2.8.5.4. 
Management of ATG Intolerance 
Patients experiencing a new, severe or life-threatening reaction to ATG and therefore unable or unwilling 
to receive the full planned cumulative dose will continue on study, but their conditioning regimen may 
then be altered as per institutional preference or practice with documentation of the deviation. 
2.8.6. Risks and Toxicities 
2.8.6.1. 
General 
The agents being used in the study are used extensively in the BMT setting and have well-defined toxicity 
profiles. In addition, there are many expected toxicities of allogeneic BMT. The following are examples of 
toxicities that are serious but not unexpected: Grade 4 cytopenias; neutropenic fever and sepsis; bacterial, 
fungal, or viral (including CMV, BK virus) infection; severe mucositis; severe GVHD; hepatic veno-occlusive 
disease; pulmonary toxicities; hemorrhagic cystitis; bleeding without hemodynamic compromise; death. 
2.8.6.2. 
Drug Information 
2.8.6.2.1. 
Fludarabine 
Fludarabine is a purine analog antimetabolite. Side effects of fludarabine include: 
1. Neurotoxicity: Agitation or confusion, blurred vision, loss of hearing, peripheral neuropathy or 
weakness have been reported. Severe neurologic effects, including blindness, coma, and death 
may occur; severe CNS toxicity is rarely seen with doses in the recommended range for 
nontransplant therapy. The dose used in this study is approximately 1.5 times the usual one-
course dose given in non-transplant settings. Doses and schedules similar to those used in this 
study have been used in adult and pediatric patients without observed increase in neurotoxicity. 
2. Anemia: Life-threatening and sometimes fatal autoimmune hemolytic anemia has been reported 
after one or more cycles of therapy in patients with or without a previous history of autoimmune 
hemolytic anemia or a positive Coombs test and who may or may not be in remission. 
Corticosteroids may or may not be effective in controlling these episodes. The majority of patients 
re-challenged developed a recurrence of the hemolytic process. 
3. Cardiovascular: Deep venous thrombosis, phlebitis, transient ischemic attack, and aneurysm (1%) 
are reported.   

13 
 
 
 
 
 
 
 
 
4. Fever: 60% develop fever. 
5. Rash: 15% develop a rash, which may be pruritic.  
6. Digestive: Gastrointestinal side effects include: nausea/vomiting (36%), diarrhea (15%), stomatitis 
(9%), anorexia (7%), GI bleeding and esophagitis (3%), mucositis (2%), liver failure, abnormal liver 
function test, constipation, dysphagia (1%) and mouth sores.  
7. Some other effects include: Chills (11%), peripheral edema (8%), myalgias (4%), osteoporosis (2%), 
pancytopenia, arthralgias (1%), dysuria (4%), urinary tract infection and hematuria (2%); renal 
failure, abnormal renal function test, and proteinuria (1%); and, very rarely, hemorrhagic cystitis 
and pulmonary toxicity.  
Dose adjustments of fludarabine are required for renal insufficiency (sections 2.5.1). 
2.8.6.2.2. 
Cyclophosphamide & Mesna 
Cyclophosphamide is an alkylating agent whose metabolites form cross-links with DNA resulting in cell 
cycle-nonspecific inhibition of DNA synthesis and function. Cyclophosphamide side effects include: 
nausea, vomiting, diarrhea, headache, dizziness, hemorrhagic cystitis, fluid weight gain/edema, SIADH, 
transaminitis, cardiomyopathy, pericarditis, rash, mucositis, alopecia, cytopenias, sterility, and rarely, 
secondary myelodysplastic syndrome and anaphylaxis. 
Dose adjustments for cyclophosphamide will not be made. 
Mesna (sodium-2-mercapto ethane sulphonate) is a prophylactic agent used to prevent hemorrhagic 
cystitis induced by the oxasophosphorines (cyclophosphamide and ifosphamide). It has no intrinsic 
cytotoxicity and no antagonistic effects on chemotherapy. Mesna binds with acrolein, the urotoxic 
metabolite produced by the oxasophosphorines, to produce a non-toxic thioether and slows the rate of 
acrolein formation by combining with 4-hydroxy metabolites of oxasophosphorines. 
The total daily dose of mesna is equal to 80% of the total daily dose of cyclophosphamide. 
At the doses used for uroprotection, mesna is virtually non-toxic. However, potential adverse effects 
include nausea and vomiting, diarrhea, abdominal pain, altered taste, rash, urticaria, headache, joint or 
limb pain, hypotension, and fatigue. 
2.8.6.2.3. 
Thymoglobulin® 
Thymoglobulin is a rabbit preparation of anti-thymocyte globulin (ATG). Common side effects include 
nausea, fever, chills, diarrhea, rash, dizziness, headache and tiredness. More serious side effects can 
include severe allergic reaction, serum sickness, easy bleeding/bruising, fast/irregular heartbeat, 
joint/muscle pain, stomach/abdominal pain, and weakness. Because this drug works by weakening the 
immune system, it lowers the ability to fight infections. No dose adjustments are required.  
2.8.6.2.4. 
Mycophenolate Mofetil (MMF) 
MMF is an ester prodrug of the active immunosuppressant mycophenolic acid (MPA).  
Side effects include: pancytopenia, infection (including sepsis, CMV, HSV, VZV, and Candida), nausea, 
vomiting, diarrhea, allergic reactions, hypertension, headache, dizziness, insomnia, hyperglycemia, 
electrolyte imbalances, rash, and leg cramps/bone pain.  

14 
 
 
 
 
 
 
 
 
Drug interactions: MMF activity is decreased with oral antacids and cholestyramine. There are no 
pharmacokinetic interactions with co-trimoxazole, oral contraceptives, or cyclosporine. Acyclovir or 
ganciclovir blood levels may increase due to competition for tubular secretion. High doses of salicylates 
or other highly protein-bound drugs may increase the free fraction of MPA and exaggerate the potential 
for myelosuppression. 
Dose adjustments: No dose adjustments are required for liver dysfunction. For renal insufficiency, MMF 
dosing should not be modified unless dialysis is needed, in which case MMF can be reduced to 25-50% of 
the starting dose. 
2.8.6.2.5. 
Tacrolimus 
Tacrolimus is a macrolide immunosuppressant that inhibits lymphocytes through calcineurin inhibition.  
Toxicities: There is a spectrum of well-described toxicities of tacrolimus. Toxicities include renal 
insufficiency, hypertension, hyperglycemia, hypomagnesemia, hypokalemia, nausea, diarrhea, headache, 
neurologic toxicity including tremor and leukoencephalopathy, infection, and rarely thrombotic 
thrombocytopenic purpura (TTP). 
Drug interactions: Tacrolimus is well absorbed orally. Tacrolimus is extensively metabolized by the 
cytochrome P-450 (CYP3A4) system and metabolized products are excreted in the urine. Drugs that may 
increase tacrolimus levels include tri-azole drugs (especially voriconazole and posaconazole), nephrotoxic 
drugs, calcium channel blockers, cimetidine and omeprazole, metoclopramide, macrolide antibiotics, 
quinupristin/dalfopristin, danazol, ethinyl estradiol, methylprednisolone, and HIV protease inhibitors. 
Drugs that may decrease tacrolimus levels include some anticonvulsants (phenobarbital, phenytoin, 
carbamazepine), caspofungin, rifamycins, and St. John’s wort.  
Dose adjustments: The tacrolimus dose is adjusted to maintain a serum trough level of 5-15 ng/mL, with 
a target of 10-15 ng/mL. Patients with hepatic or renal insufficiency should receive doses at the lower end 
of therapeutic concentrations. No dose adjustments are required in patients undergoing hemodialysis. 
Due to extreme interactions with voriconazole and posaconazole, the tacrolimus dose should be 
empirically lowered when these azoles are initiated at steady state levels of tacrolimus. Guidelines are 
provided in the table below. Dose adjustments for therapy with other azoles may be indicated. However, 
the initial tacrolimus dose (on Day 5) remains fixed.  
Dosing considerations with concurrent azole therapy: Triazole antifungal medications are expected to 
increase serum CNI levels; therefore dosages of CNI’s should be adjusted accordingly. Guidelines are 
provided in the table below. Of note, reversal of azole-mediated inhibition of CYP3A4 (and others) and P-
glycoprotein is gradual when azoles are stopped. Therefore, immediate significant dose increases in 
tacrolimus are not advised when azoles are stopped. Rather, tacrolimus dose increases should be cautious 
and based on more frequent monitoring of levels as appropriate. 
Table 1: Suggested preemptive dose reduction of tacrolimus when azoles are initiated at steady state 
levels of tacrolimus  
 
Antifungal 
Tacrolimus 

15 
 
 
 
 
 
 
 
 
 
Dose ↓ 
Comment 
Voriconazole  
67% 
Strongly advised 
Posaconazole 
67% 
Advised 
Itraconazole 
50% 
Advised 
Fluconazole 
25%  
Consider 
 
2.8.6.2.6. 
Filgrastim (G-CSF) 
Administration of G-CSF can cause bone pain, increased levels of liver enzymes and uric acid in the blood, 
thrombocytopenia, headaches, fatigue, local irritation at injection site, nausea, bleeding, fever, allergic 
reaction, splenomegaly or rupture of the spleen, worsening of pre-existing skin rashes, temporary hair 
loss, and inflammation of a blood vessel in the skin. 
2.8.6.2.7. 
Total Body Irradiation (TBI) 
TBI can cause nausea and vomiting, diarrhea, parotitis (rapid onset within 24-48 hours, usually self-
limited), generalized mild erythema (usually within 24 hours, resolving in 48-72 hours), 
hyperpigmentation, fever, mucositis, alopecia, and pancytopenia. Late effects include: cataracts (10-20%), 
hypothyroidism, nephropathy, interstitial pneumonitis, veno-occlusive disease, carcinogenesis, and 
sterility.  
2.8.6.3. 
Toxicity Grading 
Toxicities are graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.03. 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm) 
 
3. STUDY ENDPOINTS AND DEFINITIONS 
3.1. Primary Endpoint 
 
Feasibility: Feasibility will have been met with these benchmarks: the patient has the transplant, 
achieves engraftment, and survives one year. 
 
 
3.2. Secondary Endpoints 
3.2.1. Overall Survival (OS) 
 
OS at 1 year post-BMT in patients with SAA. OS is defined as the time interval from date of transplant to 
death or to last follow-up. 
 

 
16 
 
 
 
 
 
 
 
 
3.2.2. Neutrophil Engraftment 
 
Neutrophil engraftment is achieving an ANC >0.5 x109/L for three consecutive measurements on different 
days, with the first of the three days being defined as the day of neutrophil engraftment. 
3.2.3. Platelet Engraftment 
 
Platelet engraftment is defined by achieving a platelet count >20 x 109/L with no platelet transfusions in 
the preceding seven days. The first day of the sustained platelet count will be defined as the day of platelet 
engraftment. 
3.2.4. Alive with Sustained Engraftment 
 
Being alive and engrafted is defined as not having experienced death, primary graft failure, or secondary 
graft failure.  
3.2.4.1. 
Primary Graft Failure 
 
Primary graft failure is defined by the lack of neutrophil engraftment by day 56 post-BMT or <5% donor 
chimerism on all measurements up to and including day 56.  
3.2.4.2. 
Secondary Graft Failure 
 
Secondary graft failure is defined by initial neutrophil engraftment (ANC >0.5 x109/L measured for three 
consecutive measurements on different days) followed by sustained subsequent decline in ANC to < 0.5 x 
109/L for three consecutive measurements on different days or initial whole blood or marrow donor 
chimerism more than 5%, but then declining to <5% on subsequent measurements. 
3.2.5. Acute GVHD:  Acute GVHD is graded by standard criteria (Appendix 1). All suspected cases 
of acute GVHD must be confirmed histologically by biopsy of an affected organ (e.g., skin, 
liver, or gastrointestinal tract).  Date of symptom onset, date of biopsy confirmation of 
GVHD, maximum clinical grade, sites affected, and dates and types of treatment will be 
recorded.  Dates of symptom onset of initial diagnosis of GVHD (even if non-severe) and 
grade III-IV GVHD will be recorded. 
 
The cumulative incidences of acute grade III-IV and grade III-IV GVHD will be determined 
through competing risk analysis.  Treatment of disease relapse/progression/persistence 
(with the exception of planned maintenance or consolidative therapy), graft failure, and 
death are considered competing risks for GVHD for study purposes.  In addition, GVHD will 
be reported with only graft failure and death regarded as competing risks. 
3.2.6. Chronic GVHD:  Chronic GVHD is graded by both NIH consensus criteria and Seattle criteria.  
Date of onset, date of biopsy confirmation (if any), dates and types of treatment, and extent 

 
17 
 
 
 
 
 
 
 
 
will be recorded. The cumulative incidence of chronic GVHD (overall and according to 
extent) will be determined through competing risk analysis. 
 
3.2.7. Immune Reconstitution 
 
Quantitative assessments of peripheral blood CD4, CD19 and CD56 positive lymphocytes will be done 
through flow cytometric analysis at baseline, 3, 6 and 12 months post transplantation. Results will be 
tabulated according to time from transplant. 
3.2.8. Infection 
 
Infections will be tracked and reported according to section 5.2. 
3.2.9 Clonal hematopoiesis 
This will be tracked clinically only with conventional karyotyping and PNH testing. Research somatic 
mutational testing will be assessed from pre BMT samples as well as per Table 3.  
 
 

 
18 
 
 
 
 
 
 
 
 
3.3. Study Monitoring 
 
3.3.1. Follow-up Schedule 
 
The follow-up schedule for study visits is outlined in Table 2. 
 
Table 2: Follow-Up Schedule 
 
Study Visit 
Target Day Post-Transplant 
1 week 
7 ± 3 days 
2 week 
14 ± 3 days 
3 week 
21 ± 3 days 
4 week 
28 ± 3 days 
8 week 
56 ± 5 days 
12 week 
84 ± 7 days 
 
 
6 month 
180 ± 28 days 
12 month 
365 ± 45 days 
 
3.3.2. Patient Evaluations 
 
Table 3 summarizes patient clinical assessments over the course of the study. 
 
 

 
19 
 
 
 
 
 
 
 
 
Table 3: Summary of Assessments 
 
Study Assessments / Testing 
Baseline 
 
7 
14 
21 28 
56 
84 
180 
365 
Weight and height 
X 
 
 
 
 
 
 
 
 
History and physical exam 
 
 
 
 
X 
X 
X 
X 
X 
Karnofsky/Lansky Performance Status 
X 
 
 
 
X 
X 
X 
X 
X 
CBC with differential and platelet counts1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood Chemistries2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
HLA Typing & Anti-Donor Antibody Testing 
X 
 
 
 
 
 
 
 
 
Infectious Disease Titers3 
X 
 
 
 
 
 
 
 
 
LVEF or Shortening Fraction for <13 years 
X 
 
 
 
 
 
 
 
 
Pulmonary Function Tests4 
X 
 
 
 
 
 
 
 
 
Bone Marrow Aspirate for Pathology, 
Quantitative CD34 count and Cytogenetics5 
X 
 
 
 
 
X 
 
 
X 
Testing for Fanconi Anemia6 
X 
 
 
 
 
 
 
 
 
Mutational testing preBMT where clinically 
appropriate 
(May 
include 
somatic 
mutational testing; telomere length analysis 
or known gene testing) 
(X) 
not 
required 
unless 
clinically 
indicated 
by treating 
physician  
 
 
 
 
 
 
 
X 
(rep
eat 
only 
whe
n 
posi
tive 
initi
ally 
Pregnancy Test (females only) 
X 
 
 
 
 
 
 
 
 
CD4, CD19, and CD56 Counts 
(by flow cytometry when available, not 
mandatory) 
X 
 
 
 
 
 
X 
X 
X 
Serum Quantification of IgG, IgM, and IgA 
X 
 
 
 
 
 
 
 
X 
Peripheral Blood Chimerism7 
X 
 
 
 
X 
X 
X 
X 
X 

 
20 
 
 
 
 
 
 
 
 
Bone marrow chimerism 
 
 
 
 
 
X 
 
 
X 
CMV DNA Quantitative PCR Testing8 
 
 
 
 
X 
X 
X 
 
 
Toxicity Assessments9 
 
X 
X 
X 
X 
X 
X 
X 
X 
GVHD assessments 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Notes: 
1  
CBC performed three times weekly from Day 0 until ANC > 0.5 x 109/L for three consecutive 
measurements on different days. CBC then performed twice per week until Day 28, then weekly until 84 
days, then at days 180, and 365. 
2  
Blood chemistries include: creatinine, bilirubin, alkaline phosphatase, AST, ALT, ferritin (baseline 
only), and tacrolimus level. Tacrolimus levels will be measured at least once weekly until Day 84 and then 
at each follow-up visit until the drug is stopped. Blood chemistries performed twice weekly until Day 30 
and then weekly until Day 84, then at days 180, and 365.  
3  
Infectious disease titers include: CMV IgG, hepatitis B/C panel (HepB SAb, HepB SAg, HepB Core 
Ab, HepC Ab), and HIV. 
4 
DLCO (corrected for Hb), FEV1, and FVC or pulse oximetry for patients aged <8 years if unable to 
perform standard PFT. 
5  
Bone marrow aspirate and biopsy (cytogenetics is required, local MDS (somatic mutational panel 
recommended) within 60 days of enrollment. 
6 
Results of Diepoxybutane (DEB) testing on peripheral blood or comparable testing on marrow for 
Fanconi anemia at any time prior to enrollment. Required only for participants < 40 years old at the time 
of enrollment. 
7 
Chimerism to be measured by standard molecular testing of a peripheral whole blood sample. 
8 
To be done as per institutional practices. It is recommended to start at Day 28 and continue 
weekly or every other week monitoring until off all immunosuppression. 
9 
Toxicities should be monitored and reported continuously through day 365 as per section 5.2.  
10 
In order to minimize the need for research-only in-person visits, telemedicine visits may be 
substituted for in person clinical trial visits or portions of clinical trial visits where determined to be 
appropriate and where determined by the investigator not to increase the participants risks. Prior to 
initiating telemedicine for study visits the study team will explain to the participant, what a telemedicine 
visit entails and confirm that the study participant is in agreement and able to proceed with this method. 
Telemedicine acknowledgement will be obtained in accordance with the Guidance for Use of 
Telemedicine in Research. In the event telemedicine is not deemed feasible, the study visit will proceed 
as an in-person visit. Telemedicine visits will be conducted using HIPAA compliant method approved by 
the Health System and within licensing restrictions.  
 

 
21 
 
 
 
 
 
 
 
 
4. STATISTICAL CONSIDERATIONS 
Overall Study Design 
This study is designed as a Phase II trial to assess the safety and efficacy of upfront BMT using primarily 
related donors (and unrelated donors in cases of clear inherited predisposition to marrow failure), with 
Thymoglobulin® (ATG) containing preparative regimen in patients with untreated severe aplastic anemia. 
The target enrollment is 20 patients. 
The primary goal of this study is to determine whether this type of transplantation for SAA is feasible and 
safe. There will be continuous monitoring for feasibility and for safety. Feasibility will have been met with 
these benchmarks: the patient has the transplant, achieves engraftment, and survives one year. The 
safety monitoring plan is included to monitor graft failure (day 60), grade 2-4 acute graft versus host 
disease (day100), 6 month mortality (day 180), and chronic graft versus host disease (day 180). 
 
4.1. Primary Objective 
Our primary objective is to determine if it is feasible for previously untreated SAA patients to be 
transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide. 
 
4.2. Secondary Objectives 
4.2.1. To estimate overall survival at one year. 
4.2.2. To estimate full donor chimerism by day 60 
4.2.3. To estimate the cumulative incidence of non–relapse-related mortality following 
transplant. 
4.2.4. To estimate the incidences of primary and secondary graft failure following transplant. 
4.2.5. To estimate the cumulative incidences of grade II-IV and grade III-IV acute graft versus-
host disease (GVHD).  
4.2.6. To estimate the cumulative incidence of chronic graft versus-host disease (GVHD).  
4.2.7. To estimate the cumulative incidence of ANC and platelet recovery.  
4.2.8. To estimate GVHD free relapse free survival (GRFS). 
4.2.9. To summarize major transplant related toxicities and to estimate transplant related 
mortality (TRM). 
 
4.3. Early stopping guideline for feasibility 
Feasibility of non-myeloablative, partially HLA-mismatched, unrelated (or related if older patient age) 
transplantation in previously untreated SAA will be based on three benchmarks: the patient has the 
transplant, achieves engraftment, and survives one year.  Estimates of one year survival for upfront non-
myeloablative SAA transplants between July 1999 and June 2012 were obtained from the Center for 
International Blood and Bone Marrow Transplant Research (CIBMTR). For patients ≤ 20 years (N=1126) 
one year survival was 79% (95% CI: 74-84%) and in patients over the age of 20 (N=975) it was 68% (95% 
CI: 62-74%).  
 
We will use a probability-based decision rule for the study to decide if the probability of successfully 
proceeding through the study is convincingly less than 0.70. We expect, a priori, the feasibility to be high 
and that 80% of patients will meet the feasibility benchmarks. The monitoring rule will therefore use an a 

 
22 
 
 
 
 
 
 
 
 
priori optimistic Beta(8,2) prior distribution. This distribution corresponds to an assumption that 8 out of 
10 patients will proceed successfully through the study as planned and 90% certainty that feasibility is 
between .57 and .96. This stopping rule will hold enrollment if, given the data, there is at least 90% 
probability that fewer than 70% of patients are meeting the feasibility criterion. 
 
The table below gives the numbers of patients out of the number on study that would cause the study to 
be reviewed for feasibility. For example, If only two of the first nine patients are able to meet feasibility 
criterion and complete the study as expected, the study would be paused. 
 
Stop if number 
of 
patients 
successful   
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
in N patients 
5 
7 
9 
10 
12 
13 
15 
16 
18 
20 
 
Operating characteristics for feasibility:  The operating characteristics of this feasibility rule have been 
calculated based on 5000 simulations. If the posterior certainty that feasibility is 70% or less, based on 
Bayes rule and the assumption of a Beta(8,2) prior, is 90% or higher (≥ 9:1 odds against the patients 
proceeding through the study as planned), further study will be reconsidered. For data simulated with 
known probabilities of feasibility (θ), the table shows the percent of time that the feasibility rule will 
determine that the underlying proportion of patients who continue successfully through is below 70%. 
 
True feasibility (θ) 
0.30 
0.40 
0.50 
0.60 
0.70 
0.75 
0.80 
0.85 
% studies stopped 
96.5% 82.8% 51.0% 20.3% 3.5% 
1.2% 
0.2% 
0.1% 
 
4.4. Sample size and accrual 
We estimate two to three years of accrual to enroll 20 patients.  At the end of the study, according to 
the stopping rule, at least 10 patients will have met the feasibility benchmarks for the study to 
complete without a pause. We would probably not recommend this treatment if, given the data, there 
is a 90% probability that fewer than 70% of patients could continue successfully through the study. If 
11 out of 20 patients fail to complete the study successfully, there would be less than 7% probability 
that the underlying feasibility is 70% or higher. 
 
 
4.5. Stopping Rules for safety 
Mortality, graft failure, and acute and chronic graft versus host disease will be monitored after every 
patient. We will use probability-based decision rules with assumptions outlined in the table below.  
Independence was assumed between the four types of toxicities to establish the stopping boundaries. 
In practice, these endpoints are not independent and the study stopping criterion could be anti-
conservative. While this is a limitation, the lack of preliminary data precluded realistic simulations 
based on cumulative incidence or multinomial probabilities. Historical probabilities of these events in 
patients transplanted after relapse were obtained from Bacigalupo1 and Eapen2. The patients in this 

 
23 
 
 
 
 
 
 
 
 
trial will be treated upfront and therefore the incidence of these events may differ somewhat.  The 
prior probabilities for this study are modeled by beta distributions which have means that correspond 
to the historical estimates. The spread of the prior distributions is described in column 5 as intervals 
over which we are 90% certain that the estimates of the historical means are within.  The last two 
columns give thresholds for our stopping rule and the certainty with which we must be that the 
threshold is exceeded before we pause for a review of safety. For all of the endpoints, if there are 3:1 
odds that the safety threshold has been exceeded, the study will be paused for a review.     
 
Patients who develop both acute and chronic GVHD will be regarded as having adverse GVHD events for 
both stopping rules.   
 
Endpoi
nt 
Tim
e 
(day
) 
Ref.
* 
Prior 
Spread of 
prior (90% 
certainty) 
Threshol
d 
Certainty 
required 
for 
stopping 
Graft 
fail 
60 
17% 
Beta(2,10
) 
3.3 
- 
36.4% 
15% 
75% 
aGVHD 
100 
31% 
Beta(3,6.
5) 
10.4 
-
57.4% 
35% 
75% 
Mortali
ty 
180 
20% 
Beta(2,8) 
4.1 
– 
42.9% 
25% 
75% 
cGVHD 
180 
50% 
Beta(5,5) 
25.1 
– 
74.9% 
50% 
75% 
 
* Historical estimates taken from references for patients transplanted after relapse.  
 
Stopping rule for graft failure: 
Stop if GF 
2 
3 
4 
5 
and 
N 
patients 
2-6 
7-11 
12-17 
18-20 
 
Stopping rule for acute graft versus host disease: 
Stop if aGVHD 
3 
4 
5 
6 
7 
8 
9 
10 
and N patients 
3-4 
5-6 
7-9 
10-11 
12-14 
15-16 
17-19 
20 
 
Stopping rule for death: 
Stop if death 
3 
4 
5 
6 
7 
8 
and 
N 
patients 
3-4 
5-8 
9-11 
12-15 
16-19 
20 
 
Stopping rule for chronic graft versus host disease: 
Stop if cGVHD 
3 
4 
5 
6 
7 
8 
and 
N 
patients 
3 
4-5 
6-7 
8-9 
10 
11-12 
 
Stop if cGVHD 
9 
10 
11 
12 

 
24 
 
 
 
 
 
 
 
 
and 
N 
patients 
13-14 
15-16 
17-18 
19-20 
 
Operating characteristics of safety stopping rule: 
We have assumed independence for establishing our safety monitoring stopping rules. Operating 
characteristics for each event, assuming the others do not censor or otherwise mask the event, are given 
below. In practice, these endpoints are not independent and the study stopping criterion could be anti-
conservative.    
 
True event prob. 
(θ) 
0.10 
.15 
.20 
.25 
.30 
.35 
.40 
.50 
.55 
.60 
Graft 
failure 
stopped (%) 
17.2 
36.5 
58.1 
75.7 
86.6 
94.2 
97.2 
99.7 
100 
100 
aGVHD 
stopped  (%) 
0.4  
2.0 
5.2 
9.9 
19.8 
32.9 
48.9 
77.1 
88.0 
94.1 
Death 
Stopped (%) 
0.9 
4.3 
12.3 
26.7 
43.1 
59.3 
75.5 
93.4 
97.2 
99.2 
cGVHD 
Stopped (%) 
0.1 
0.6 
1.6 
3.4 
6.6 
12.5 
19.5 
44.5 
58.8 
74.1 
 
 
4.6. Analysis of Primary Endpoint 
The following table shows the 90% credible intervals for the underlying probability 
of feasibility, based on different numbers of patients successfully meeting the 
feasibility benchmarks, using a Beta(8,2) prior. The analysis plan is two-sided (5% in 
each tail), allowing for the full range of possible outcomes, while sample size is based 
on a one-sided consideration (10% in the upper tail). As an example of the final 
inference, if 17 out of 20 patients meet the feasibility criterion, we will be fairly 
confident that feasibility is 70% or higher. 
 
Outcome and 90% Credible Interval Outcome and 90% Credible Interval 
  10 out of 20        (45.1, 74.1) 
16 out of 20        (67.1, 90.6)   
  11 out of 20        (48.6, 77.1) 
17 out of 20        (71.2, 93.0) 
  12 out of 20        (52.1, 80.0) 
18 out of 20        (75.4, 95.1) 
  13 out of 20        (55.7, 82.8) 
19 out of 20        (79.8, 97.1) 
  14 out of 20        (59.4, 85.5) 
20 out of 20        (87.2, 100.0) 
  15 out of 20        (63.2, 88.1) 
 
 
 
4.7. Analysis of Secondary Endpoints 
4.7.1. Standard life table methods will be used to report OS. We will report the six-month, one, 
and two year OS.  
4.7.2.  We will estimate full donor chimerism by day 60 with an exact 90% binomial confidence 
interval. 

 
25 
 
 
 
 
 
 
 
 
4.7.3. NRM: To estimate the cumulative incidence of non–relapse-related mortality following 
transplant, a cumulative incidence curve will be produced. Incidence of NRM will be 
estimated at 60 days, 100 days, six months, and one year along with 90% confidence 
intervals. Relapse or death will be considered as competing events 
4.7.4. Graft failure: To estimate the day 60 and overall incidence of primary and secondary graft 
failure following transplant. Exact binomial 90% confidence intervals will be reported. 
4.7.5. Acute GVHD: To estimate the cumulative incidence of grade II-IV and grade III-IV acute 
GVHD from day of transplant. The first day of acute GVHD onset for a given grade will be 
used to estimate the cumulative incidence curves. Overall cumulative incidence will be 
estimated along with a 90% confidence interval as well as at 100 days post-transplant. Graft 
failure, disease progression or death prior to occurrence of acute GVHD will be considered 
as competing events. 
4.7.6. Chronic GVHD: To estimate the cumulative incidence and severity of chronic GVHD from 
day of transplant, the first day of clinical onset of chronic GVHD will be used to estimate a 
cumulative incidence curve. Incidences of chronic GVHD at one and two years post-
transplant will be estimated along with 90% confidence intervals. Death, disease 
progression, or graft failure prior to occurrence of chronic GVHD will be considered as 
competing events. 
4.7.7. The cumulative incidence of ANC and platelet recovery will be reported. Death before 
count recovery will be considered a competing event. Platelet recovery to both 20K and 50K 
will be reported. 
4.7.8. GRFS is defined as the interval from Day 0 to date of first grade 3-4 aGVHD, or chronic 
GVHD, or relapse, death from any cause, or last patient evaluation. Patients without grade 
3-4 aGVHD, chronic GVHD, or who have not progressed or died will be censored at the last 
date they were assessed. Standard life table methods will be used to report GRFS. We will 
report the six-month, one, and two year GRFS.  
4.7.9. Transplant related toxicities will be summarized descriptively with proportions and exact 
binomial confidence intervals. TRM: Estimate the probability of death due to causes 
unrelated to the underlying disease. Standard life table methods will be used to report TRM. 
 
Statistical References: 
[1] Bacigalupo, A., Socie’, G., Lanino, E., Prete, A., Locatelli, F., Locasciulli, A., Cesaro, S.,  Shimoni, 
A., Marsh, J., Brune, M., Van Lint, M.,  Oneto, R., and Passweg, J. Fludarabine, cyclophosphamide, 
antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, 
in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. 
Haematologica, 95(6): 976–982, 2010. 
 
[2] Eapen, M., Le Rademacher, J., Antin, J.H., Champlin, R.E., Carreras, J., Fay, J., Passweg, J.R., Tolar, 
J., Horowitz, M.M., Marsh, J.C., Deeg, H.J.  Effect of stem cell source on outcomes after unrelated donor 
transplantation in severe aplastic anemia. Blood, 118(9):2618-21, 2011.  
  
 

 
26 
 
 
 
 
 
 
 
 
4.7.10. Analysis of Secondary Endpoints 
 
Proportion of Patients Alive and Engrafted: 
The proportion of patients alive and engrafted at one year will be estimated along with a 95% confidence 
interval. 
Neutrophil Engraftment 
Cumulative incidence of neutrophil engraftment at Day 56 will be estimated with a 95% confidence 
interval using the cumulative incidence function with death prior to neutrophil engraftment as the 
competing risk.  
Platelet Engraftment 
Cumulative incidence of platelet engraftment at Day 100 will be estimated with a 95% confidence interval 
using the cumulative incidence function with death prior to platelet engraftment as the competing risk.  
Primary and Secondary Graft Failure 
The frequency and proportion of patients experiencing graft failure by Day 56 and the proportion of 
patients who have engrafted who subsequently experience secondary graft failure will be described with 
95% confidence interval. 
Grade II – IV Acute GVHD 
Cumulative incidence of Grade II – IV acute GVHD at Day 100 will be estimated with a 95% confidence 
interval using the cumulative incidence function with death prior to Grade II – IV acute GVHD as the 
competing risk.  
Chronic GVHD 
Cumulative incidence of chronic GVHD at one year will be estimated with a 95% confidence interval using 
the cumulative incidence function with death prior to chronic GVHD as the competing risk.  
Immunologic Reconstitution  
Immune reconstitution assays including CD4, CD19, and CD56 will be measured pre-HCT, and at 3, 6, and 
12 months post HCT. These will be summarized at each time point using descriptive statistics.  
Incidence of Infectious Complications 
The number of infections and the number of patients experiencing infections will be tabulated. Incidences 
of CMV viremia and disease, EBV viremia and PTLD will be reported. 
 
 
 

 
27 
 
 
 
 
 
 
 
 
5. DATA MANAGEMENT 
 
Data will be maintained on case report forms and appropriate Cell Therapy Laboratory 
spreadsheets and forms. The research team will make assessments of GVHD.  Evaluation by 
history and physical examination for GVHD will be performed as per BMT unit standards. For study 
purposes, weekly GVHD summaries will be taken from these standard examination from Day 14- 
Day 60.Hematopoietic engraftment will be assessed by the BMT attending and the PI. The PI will 
be responsible for evaluation of chimerism data and weekly overall toxicities.  
5.1. Data and Safety Monitoring  
 
At the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, the Associate 
Director for Clinical Research, Clinical Research Review Committee (CRC), SKCCC Safety 
Monitoring Committee (SMC), CRO Quality Assurance Group, and the PI share monitoring 
responsibilities.   
5.2. Internal Data Monitoring and Adverse Event reporting 
 
The PI will review data to assure the validity of data, as well as, the safety of the subjects. The PI 
will also monitor the progress of the trial. The PI will review safety reports and clinical trial efficacy 
endpoints and to confirm that the safety outcomes favor continuation of the study. 
The PI will be responsible for maintaining the clinical protocol, reporting adverse events, assuring 
that consent is obtained and documented, reporting of unexpected outcomes, and reporting the 
status of the trial in the continuing renewal report submitted to the IRB and to the trial monitoring 
review group. Content of the continuing renewal report at a minimum should include year-to-
date and full trial data on: accrual and eligibility, protocol compliance, treatment administration, 
toxicity and ADR reports, response, survival, regulatory compliance, compliance with prearranged 
statistical goals. The report should be submitted in a timely manner according to the schedule 
defined by Johns Hopkins Medicine Institutional Review Board.  
For study purposes, the following will be recorded and reported as Serious Adverse Events in 
accordance with IRB requirements: 
a. Events that are unexpected and possibly, probably, or definitely related to transplant will 
be reported in real-time; all other events (e.g. neutropenic fever) will be reported on a 
yearly basis. 
b. Any death before Day 100, and any later death which is possibly, probably, or definitely 
transplant-related, will be reported to IRB in real-time. 
c. Graft failures associated with failure of neutrophil recovery to >500/mm³ by Day 60 after 
BMT. 
d.  
The agents being used in the study are FDA approved.  These agents are used 
extensively in the Bone Marrow Transplant setting and have well defined toxicity 
profiles.  In addition, there are many expected toxicities related to a bone marrow 
transplant.  For these reasons, toxicities will be captured and recorded/graded if 

 
28 
 
 
 
 
 
 
 
 
the adverse event interferes with the subject’s daily function and are considered 
clinically significant.  We will capture and grade all these events structured around 
the categories of the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.0 for the first 60 days post BMT.  
 
Since this trial is an IPOP, inpatient and out-patient trial, the definition of an 
adverse event ‘interfering with daily function’ and ‘clinically significant’ will be 
events that require hospitalization (outside of institutional standards for IPOP 
needs or pediatric re-hospitalization standards for this ambulatory care based on 
the outpatient clinic resources and availability).  Due to the nature of marrow 
transplantation, 
readmissions 
to 
the 
hospital 
are 
expected; 
therefore 
hospitalization (either inpatient or IPOP) during the first 60 days post-transplant 
will not be considered a SAE.  For example, if a patient has a neutropenic fever 
that requires hospitalization, then ‘neutropenic fever’ will be captured and graded 
as an adverse event.  An example of a non-captured event is if a patient has 
hypotension that is corrected by fluid administration in the outpatient setting.  This 
will not be captured as an adverse event unless the patient requires a hospital 
admission for further treatment of the hypotension. 
 
Once the patient becomes hospitalized, the above definition of ‘requiring 
hospitalization’ cannot be used to capture adverse events.  For these already 
hospitalized patients, events will only be recorded once the event is greater than 
a grade 3 or 4 as stated below. 
 
In addition, the following toxicities will be tracked for study purposes:  
a. Clinically significant infections during the first year of transplant, with the exception of 
uncomplicated, culture-negative neutropenic fever. This includes CMV disease, other 
clinically significant documented viral infections, bacterial infections, and proven or 
probable invasive fungal infections. 
b. CMV reactivation (including asymptomatic reactivation) 
c. Hepatic veno-occlusive disease 
d. All grade 3-5 AEs by CTCAE 4.03 criteria 
 
5.3. External Data Monitoring and Auditing  
 
 The SKCCC Compliance Monitoring Program will provide external monitoring for JHU-affiliated 
sites in accordance with SKCCC DSMP (Version 6.0, 02/21/2019).  
5.4. Safety Monitoring  
 
 The SKCCC Safety Monitoring Committee (SMC Subcommittee will determine the level of patient 
safety risk and level/frequency of monitoring.The SMC is charged with ensuring the safety of 
participants and the validity and integrity of the data and the appropriate closure of studies for 
which significant benefits or risks have been uncovered. The Committee is responsible for 
continuous, ongoing review of the conduct of the trial, including adherence to study design, 
documentation of appropriate monitoring, and proper reporting of protocol problems and events. 

 
29 
 
 
 
 
 
 
 
 
Inherent in this process is the goal of enhancing the quality of the research by providing the 
investigator with constructive criticism. The SMC membership includes physicians and other 
representatives from various Center Programs, biostatistics, data management, nursing, and 
quality assurance.  
5.5. Risks and Benefits 
5.5.1. Risks and toxicity 
The major toxicity of using bone marrow from HLA-mismatched donors is GVHD. Using non-
myeloablative conditioning regimens and stem cell products from peripheral blood, we would 
expect the incidence of GVHD in this study to be in the 40-50% range using unmanipulated bone 
marrow as the source of stem cells.  
Another significant risk is failure-to-engraft due to rejection by host lymphocytes. However, 
because of the non-myeloablative nature of the conditioning regimen we would expect patients 
to have full autologous, hematologic recovery.  
Infection is a major cause of morbidity and mortality in the peri-transplant period (<100d post-
BMT). However, given current supportive care and the intensive infection prophylaxis of this 
protocol, we expect the risk to be acceptable. Prolonged neutropenia may increase this risk in the 
case of graft rejection, however. 
Other risks that may be associated with fludarabine chemotherapy include prolonged 
immunosuppression of T-lymphocytes increasing the incidence of PCP and viral infections. The 
extent of this risk is unclear at present. Patients will receive appropriate PCP prophylaxis and will 
be monitored carefully for evidence of infection by viruses such as CMV, BK and adenovirus. Major 
risks associated with cyclophosphamide chemotherapy include hemorrhagic cystitis and 
congestive heart failure.  
Relapse of the underlying disease also may occur.  
5.5.2. Benefits 
The potential benefits of this trial are prolongation of overall survival. 
5.6. Informed Consent 
Patients eligible for marrow grafting are completely evaluated and then presented and approved 
for transplant at the Bone Marrow Transplant group conference. The group's recommendations 
are discussed with the patient. If the patient is approved for BMT, the marrow processing 
procedure itself, the risks of the preparative regimen, risks of BMT complications including 
infection and GVHD and alternate forms of therapy are presented as objectively as possible. For 
pediatric patients (<18 yr of age) assent is obtained from the patient and informed consent is 
obtained from all parents. Informed consent is obtained  
from the recipient using the 
forms approved by the IRB.         
5.7. On-study Date 
 
Date of consent signing.  
5.8. Off-study Date 
Upon completion of Day 365 evaluations, subjects have completed their participation on 
this study. Participants will be taken off study early in the event of: 

 
30 
 
 
 
 
 
 
 
 
1. Death  
2. Participant decision (or decision by a parent or guardian on behalf of a minor) 
 
 

 
31 
 
 
 
 
 
 
 
 
Appendix 1. Consensus conference clinical grading of acute GVHD 
 
Clinical Staging 
Stage 
Skin 
Liver: 
Total 
Bilirubin 
Intestinal Tract: Diarrhea 
0 
No rash 
<2.0 mg/dL 
<500 ml/day 
1 
<25% of skin surface 
2.0-3.0 
500-1000 ml/day 
2 
25-50% 
3.1-6.0 
1001-1500 ml/day 
3 
Erythroderma 
6.1-15.0 
>1500 ml/day 
4 
Erythroderma with bullae 
and desquamation 
>15.0 
Severe abdominal pain with or 
without ileus 
 
Clinical Grading 
Grade 
Skin* 
Liver 
GI 
I 
1-2 
0 
0 
II 
3 
1 
1 
III 
- 
2-3 
2-4 
IV 
4 
4 
- 
*Each column identifies minimum stage for organ grade 
 
 
 
 
 
 
 
 
 
 

 
32 
 
 
 
 
 
 
 
 
Appendix 2. Ideal Body Weight and Adjusted Ideal Body Weight Calculations 
 
Ideal Body Weight Formula 
 
Males: 50 kg + (2.3 x the number of inches > 5 feet) 
Females: 45 kg + (2.3 x the number of inches > 5 feet) 
 
Adjusted Ideal Body Weight Formula 
 
[(actual weight – ideal weight) x 25%] + ideal weight 
Note:  If actual weight < ideal, use actual weight. 
 
If actual weight > ideal, use corrected ideal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
33 
 
 
 
 
 
 
 
 
References Cited 
 
1 
A. Bacigalupo, R. Brand, R. Oneto, B. Bruno, G. Socie, J. Passweg, A. Locasciulli, M. T. 
Van Lint, A. Tichelli, S. McCann, J. Marsh, P. Ljungman, J. Hows, P. Marin, and H. 
Schrezenmeier, 'Treatment of Acquired Severe Aplastic Anemia: Bone Marrow 
Transplantation Compared with Immunosuppressive Therapy--the European Group for 
Blood and Marrow Transplantation Experience', Semin Hematol, 37 (2000), 69-80. 
2 
A. Bacigalupo, R. Oneto, B. Bruno, G. Socie, J. Passweg, A. Locasciulli, M. T. Van Lint, 
A. Tichelli, S. McCann, J. Marsh, P. Ljungman, J. Hows, P. Marin, and H. Schrezenmeier, 
'Current Results of Bone Marrow Transplantation in Patients with Acquired Severe 
Aplastic Anemia. Report of the European Group for Blood and Marrow Transplantation. 
On Behalf of the Working Party on Severe Aplastic Anemia of the European Group for 
Blood and Marrow Transplantation', Acta Haematol., 103 (2000), 19-25. 
3 
A. Bacigalupo, G. Socie, H. Schrezenmeier, A. Tichelli, A. Locasciulli, M. Fuehrer, A. M. 
Risitano, C. Dufour, J. R. Passweg, R. Oneto, M. Aljurf, C. Flynn, V. Mialou, R. M. 
Hamladji, J. C. Marsh, Blood Aplastic Anemia Working Party of the European Group for, 
and Transplantation Marrow, 'Bone Marrow Versus Peripheral Blood as the Stem Cell 
Source for Sibling Transplants in Acquired Aplastic Anemia: Survival Advantage for Bone 
Marrow in All Age Groups', Haematologica, 97 (2012), 1142-8. 
4 
J. Bolanos-Meade, E. J. Fuchs, L. Luznik, S. M. Lanzkron, C. J. Gamper, R. J. Jones, and 
R. A. Brodsky, 'Hla-Haploidentical Bone Marrow Transplantation with Posttransplant 
Cyclophosphamide Expands the Donor Pool for Patients with Sickle Cell Disease', Blood, 
120 (2012), 4285-91. 
5 
R. A. Brodsky, and R. J. Jones, 'Aplastic Anaemia', The Lancet, 365 (2005), 1647-56. 
6 
L. M. Burroughs, A. E. Woolfrey, B. E. Storer, H. J. Deeg, M. E. Flowers, P. J. Martin, P. 
A. Carpenter, K. Doney, F. R. Appelbaum, J. E. Sanders, and R. Storb, 'Success of 
Allogeneic Marrow Transplantation for Children with Severe Aplastic Anaemia', Br J 
Haematol, 158 (2012), 120-8. 
7 
B. M. Camitta, E. D. Thomas, D. G. Nathan, R. P. Gale, K. J. Kopecky, J. M. Rappeport, 
G. Santos, E. C. Gordon-Smith, and R. Storb, 'A Prospective Study of Androgens and Bone 
Marrow Transplantation for Treatment of Severe Aplastic Anemia', Blood, 53 (1979), 504-
14. 
8 
R. E. Champlin, W. S. Perez, J. R. Passweg, J. P. Klein, B. M. Camitta, E. Gluckman, C. 
N. Bredeson, M. Eapen, and M. M. Horowitz, 'Bone Marrow Transplantation for Severe 
Aplastic Anemia: A Randomized Controlled Study of Conditioning Regimens', Blood, 109 
(2007), 4582-85. 
9 
A. C. Dietz, P. J. Orchard, K. S. Baker, R. H. Giller, S. A. Savage, B. P. Alter, and J. Tolar, 
'Disease-Specific Hematopoietic Cell Transplantation: Nonmyeloablative Conditioning 
Regimen for Dyskeratosis Congenita', Bone Marrow Transplant., 46 (2011), 98-104. 
10 
M. A. Kharfan-Dabaja, Z. K. Otrock, A. Bacigalupo, R. A. Mahfouz, F. Geara, and A. 
Bazarbachi, 
'A 
Reduced 
Intensity 
Conditioning 
Regimen 
of 
Fludarabine, 
Cyclophosphamide, Antithymocyte Globulin, Plus 2 Gy Tbi Facilitates Successful 
Hematopoietic Cell Engraftment in an Adult with Dyskeratosis Congenita', Bone Marrow 
Transplant, 47 (2012), 1254-5. 
11 
J. Konopacki, R. Porcher, M. Robin, S. Bieri, J. M. Cayuela, J. Larghero, A. Xhaard, A. L. 
Andreoli, N. Dhedin, A. Petropoulou, P. Rodriguez-Otero, P. Ribaud, H. Moins-

 
34 
 
 
 
 
 
 
 
 
Teisserenc, M. Carmagnat, A. Toubert, Y. Chalandon, G. Socie, and R. Peffault de Latour, 
'Long-Term Follow up after Allogeneic Stem Cell Transplantation in Patients with Severe 
Aplastic Anemia after Cyclophosphamide Plus Antithymocyte Globulin Conditioning', 
Haematologica, 97 (2012), 710-6. 
12 
L. Luznik, J. Bolanos-Meade, M. Zahurak, A. R. Chen, B. D. Smith, R. Brodsky, C. A. 
Huff, I. Borrello, W. Matsui, J. D. Powell, Y. Kasamon, S. N. Goodman, A. Hess, H. I. 
Levitsky, R. F. Ambinder, R. J. Jones, and E. J. Fuchs, 'High-Dose Cyclophosphamide as 
Single-Agent, Short-Course Prophylaxis of Graft-Versus-Host Disease', Blood, 115 
(2010), 3224-30. 
13 
L. Luznik, and E. J. Fuchs, 'High-Dose, Post-Transplantation Cyclophosphamide to 
Promote Graft-Host Tolerance after Allogeneic Hematopoietic Stem Cell Transplantation', 
Immunol.Res., 47 (2010), 65-77. 
14 
J. C. Marsh, V. Gupta, Z. Lim, A. Y. Ho, R. M. Ireland, J. Hayden, V. Potter, M. B. Koh, 
M. S. Islam, N. Russell, D. I. Marks, G. J. Mufti, and A. Pagliuca, 'Alemtuzumab with 
Fludarabine and Cyclophosphamide Reduces Chronic Graft-Versus-Host Disease after 
Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia', Blood, 118 (2011), 
2351-7. 
15 
M. A. Pulsipher, N. S. Young, J. Tolar, A. M. Risitano, H. J. Deeg, P. Anderlini, R. Calado, 
S. Kojima, M. Eapen, R. Harris, P. Scheinberg, S. Savage, J. P. Maciejewski, R. V. Tiu, N. 
DiFronzo, M. M. Horowitz, and J. H. Antin, 'Optimization of Therapy for Severe Aplastic 
Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of 
an International Working Group on Severe Aplastic Anemia Convened by the Blood and 
Marrow Transplant Clinical Trials Network, March 2010', Biol Blood Marrow Transplant, 
17 (2011), 291-9. 
16 
J. E. Sanders, A. E. Woolfrey, P. A. Carpenter, B. E. Storer, P. A. Hoffmeister, H. J. Deeg, 
M. E. Flowers, and R. F. Storb, 'Late Effects among Pediatric Patients Followed for Nearly 
4 Decades after Transplantation for Severe Aplastic Anemia', Blood, 118 (2011), 1421-8. 
17 
H. Schrezenmeier, J. R. Passweg, J. C. Marsh, A. Bacigalupo, C. N. Bredeson, E. 
Bullorsky, B. M. Camitta, R. E. Champlin, R. P. Gale, M. Fuhrer, J. P. Klein, A. 
Locasciulli, R. Oneto, A. V. Schattenberg, G. Socie, and M. Eapen, 'Worse Outcome and 
More Chronic Gvhd with Peripheral Blood Progenitor Cells Than Bone Marrow in Hla-
Matched Sibling Donor Transplants for Young Patients with Severe Acquired Aplastic 
Anemia', Blood, 110 (2007), 1397-400. 
18 
G. Socie, M. Henry-Amar, A. Bacigalupo, J. Hows, A. Tichelli, P. Ljungman, S. R. 
McCann, N. Frickhofen, E. Van't Veer-Korthof, and E. Gluckman, 'Malignant Tumors 
Occurring after Treatment of Aplastic Anemia. European Bone Marrow Transplantation-
Severe Aplastic Anaemia Working Party', N Engl J Med, 329 (1993), 1152-7. 
19 
S. B. Wang, L. Li, X. H. Pan, D. M. Hu, L. H. Peng, L. Liu, Z. J. Xie, B. Yin, X. J. Sun, J. 
Yu, and Y. Liang, 'Engraftment of Heavily Transfused Patients with Severe Aplastic 
Anemia with a Fludarabine-Based Regimen', Clin Transplant, 27 (2013), E109-15. 
20 
N. S. Young, R. T. Calado, and P. Scheinberg, 'Current Concepts in the Pathophysiology 
and Treatment of Aplastic Anemia', Blood, 108 (2006), 2509-19.